Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 857

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 857
---
 extent such exemption from liability or limitation thereof is not permitted under the DGCL, as amended. Our bylaws provide for indemnification of our directors and officers to the maximum extent permitted by the DGCL. Item 21. Exhibits and Financial Statement Schedules. (a) Exhibits EXHIBIT INDEX

| ​ 
 ​ 
 ​ | ExhibitNo. 
        2.1 
        2.2 | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Description                                                                                                                                                                                                                                                            
 Business Combination Agreement, dated November 30, 2022, by and among Iris Acquisition Corp, Iris Parent Holding Corp., Liminatus Pharma, LLC, Liminatus Pharma Merger Sub, Inc. and SPAC Merger Sub, Inc. (included as Annex A to the proxy statement/prospectus).*** 
 Amendment to Business Combination Agreement, dated as of June 1, 2023, by and among the Company, Iris Parent Holding Corp. and Liminatus Pharma, LLC (included as Annex A to the proxy statement/prospectus).***                                                       | ​ 
 ​ 
 ​ |
|:--|-----------:|:--|:--|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--|
| ​ |        2.3 | ​ | ​ | Second Amendment to Business Combination Agreement, dated as of August 14, 2023, by and among Iris Acquisition Corp, Iris Parent Holding Corp. and Liminatus Pharma, LLC (included as Annex A to the proxy statement/prospectus).***                                   | ​ |
| ​ |        2.4 | ​ | ​ | Third Amendment to Business Combination Agreement, dated as of March 9, 2024, by and among Iris Acquisition Corp, Iris Parent Holding Corp. and Liminatus Pharma, LLC (included as Annex A to the proxy statement/prospectus).***                                      | ​ |
| ​ |        2.5 | ​ | ​ | Fourth Amendment to Business Combination Agreement, dated as of July 19, 2024, by and among Iris Acquisition Corp, Iris Parent Holding Corp. and Liminatus Pharma, LLC (included as Annex A to the proxy statement/prospectus).***                                     | ​ |
| ​ |        2.6 | ​ | ​ | Fifth Amendment to Business Combination Agreement, dated as of August 16, 2024, by and among Iris Acquisition Corp, Iris Parent Holding Corp. and Liminatus Pharma, LLC (included as Annex A to the proxy